Sensitivity analysis of progression-free survival with dependent withdrawal

Statistics in Medicine

Volumn 27, Issue 8, 2008, Pages 1180-1198

  Ruan, Ping K ^a   Gray, Robert J ^b  

^a CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Bootstrap variance estimation; Dependent censoring; EM algorithm; Log rank test; Sensitivity analysis; Survival analysis

Indexed keywords

CISPLATIN; GEMCITABINE; PACLITAXEL;

ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG WITHDRAWAL; HUMAN; INFORMATION PROCESSING; LUNG CANCER; MATHEMATICAL ANALYSIS; MAXIMUM LIKELIHOOD METHOD; METHODOLOGY; OUTCOME ASSESSMENT; PROBABILITY; SCORING SYSTEM; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; SURVIVAL RATE; TIME; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VARIANCE;

ALGORITHMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ENDPOINT DETERMINATION; HUMANS; LUNG NEOPLASMS; MEDICAL ONCOLOGY; MODELS, STATISTICAL; PATIENT DROPOUTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SENSITIVITY AND SPECIFICITY;

EID: 40849126826     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.3015     Document Type: Article

References (14)

1. Schiller JH, Harrington D, Belani C, Langer CJ, Sandler AB, Krook JE, Zhu J, Johnson DH. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. The New England Journal of Medicine 2002; 346(2):92-98.
2. Johnson JR, Williams G, Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. Journal of Clinical Oncology 2003; 21:1404-1411.
3. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data (2nd edn). Wiley: New York, 2002.
4. Cox DR. The analysis of exponentially distributed lifetimes with two types of failure. Journal of the Royal Statistical Society, Series B 1959; 21:411-421.
5. Tsiatis AA. A nonidentifiability aspect of the problem of competing risks. Proceedings of the National Academy of Sciences of the United States of America 1975; 72:20-22.
6. Moeschberger ML, Klein JP. Statistical methods for dependent competing risks. Lifetime Data Analysis 1995; 1:195-204.
7. Hogan J, Laird N. Model-based approach to analysing incomplete longitudinal and failure time data. Statistics in Medicine 1997; 16:259-272.
8. Little RJA. Modeling the drop-out mechanism in repeated-measures studies. Journal of the American Statistical Association 1995; 90:1112-1121.
9. Rotnitzky A, Scharfstein DO, Su TL, Robins JM. Methods for conducting sensitivity analysis of trails with potentially non-ignorable competing causes of censoring. Biometrics 2001; 57:103-113.
10. Scharfstein DO, Robins JM, Eddings W, Rotnitzky A. Inference in randomized studies with informative censoring and discrete time-to-event endpoints. Biometrics 2001; 57:404-413.
11. Scharfstein DO, Robins JM. Estimation of the failure time distribution in the presence of informative censoring. Biometrika 2002; 89:617-634.
12. Shardell M, Scharfstein DO, Bozzette SA. Survival curve estimation for informatively coarsened discrete event-time data. Statistics in Medicine 2007; 26:2184-2202.
13. Siannis F, Copas J, Lu G. Sensitivity analysis for informative censoring in parametric survival models. Biostatistics 2005; 6:77-91.
14. Clayton DG. A model for association in bivariate life tables and its application in epidemiological studies of familial tendency in chronic disease epidemiology. Biometrika 1978; 65:141-151.